Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Telix Pharma
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Telix Appoints Paul Schaffer as Chief Technology Officer
2025-04-07 07:09
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
2025-04-02 03:30
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
2025-03-21 08:38
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
2025-03-18 06:52
Telix Adds Lead-212 Isotope Production Capability
2025-03-13 06:48
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
2025-03-04 05:58
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
2025-02-26 08:49
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
2025-02-20 20:23
Illuccix® Approved in the United Kingdom
2025-02-13 05:30
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
2025-01-31 06:01
Telix Completes Acquisition of RLS (USA) Inc.
2025-01-28 05:40
Illuccix® Receives European Approval
2025-01-17 06:14
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
2025-01-14 05:43
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
2025-01-13 15:12
Scintimun® Commercialization Partnership with Curium Pharma
2025-01-13 13:08
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
2025-01-13 06:34
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
2024-12-31 04:45
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
2024-12-30 06:00
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
2024-12-19 17:02
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
2024-11-28 17:22
1
2
3
4
5
9